Scancell Holdings Plc (LON:SCLP)’s share price reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as GBX 5 ($0.07) and last traded at GBX 5 ($0.07), with a volume of 100000 shares. The stock had previously closed at GBX 5.15 ($0.07).
The firm has a market capitalization of $19.39 million and a PE ratio of -3.33.
TRADEMARK VIOLATION NOTICE: This news story was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.com-unik.info/2019/04/16/scancell-sclp-reaches-new-1-year-low-at-5-00.html.
Scancell Holdings plc engages in the discovery and development of novel monoclonal antibodies and vaccines for the treatment of cancer in the United Kingdom. The company's products include SCIB1, a plasmid DNA vaccine, which is in Phase I/II clinical trials for the treatment of melanoma; SCIB2 to treat lung cancer antigen; and Modi-1, which is in the pre-clinical development to treat triple negative breast cancer, ovarian cancer, and sarcoma.
Further Reading: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.